MedPage Today) -- A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results from the KEYNOTE-A18 trial...
.png)
3773 Howard Ave Las Vegas, NV
877-749-7128 ext. 500
Bruce.Oliver@REIPremiumCapitalLender.com
Copyright © 2023 privatemoneybroker. All Rights Reserved
